JDS (4190) reported revenue of NT$180.9 million for Oct 2026, -1.5% year on year and -6.7% from the previous month. Revenue for Jan–Oct 2026 was NT$1.77 billion (-4.7% year on year).
In Oct 2026, it ranked No. 47 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$180.9 million | -1.5% | -6.7% |
| Sep 2026 | NT$194 million | -9.8% | +19.1% |
| Aug 2026 | NT$162.9 million | -1.0% | +3.6% |
| Jul 2026 | NT$157.2 million | -7.7% | -2.9% |
| Jun 2026 | NT$162 million | -8.3% | -8.9% |
| May 2026 | NT$177.8 million | +1.8% | -1.1% |
| Apr 2026 | NT$179.9 million | +5.2% | -13.9% |
| Mar 2026 | NT$208.9 million | -0.5% | +51.0% |
| Feb 2026 | NT$138.3 million | -22.9% | -33.2% |
| Jan 2026 | NT$207 million | -2.2% | -2.6% |
| Dec 2025 | NT$212.4 million | +11.0% | +6.8% |
| Nov 2025 | NT$198.8 million | +2.1% | +8.2% |
| Oct 2025 | NT$183.7 million | -0.2% | -14.6% |
| Sep 2025 | NT$215.2 million | +19.3% | +30.7% |
| Aug 2025 | NT$164.6 million | -17.3% | -3.4% |
| Jul 2025 | NT$170.3 million | -11.4% | -3.6% |
| Jun 2025 | NT$176.7 million | -3.8% | +1.1% |
| May 2025 | NT$174.8 million | -12.4% | +2.2% |
| Apr 2025 | NT$171 million | -11.9% | -18.6% |
| Mar 2025 | NT$210 million | +4.0% | +17.0% |
| Feb 2025 | NT$179.4 million | +12.9% | -15.2% |
| Jan 2025 | NT$211.6 million | +5.3% | +10.6% |
| Dec 2024 | NT$191.3 million | -26.5% | -1.8% |
| Nov 2024 | NT$194.7 million | -6.9% | +5.9% |
| Oct 2024 | NT$184 million | -20.5% | +2.0% |
Jan–Oct 2026 cumulative: NT$1.77 billion (-4.7% YoY)
Other Biotech & Medical companies
Compare with peers: JDS vs PEC / JDS vs Lotus Pharm / JDS vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16